{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:03:17Z","timestamp":1774418597689,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04087-6","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:42:07Z","timestamp":1761806527000},"page":"1119-1137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the infusion: nursing at the vanguard of cytokine release syndrome rescue in CAR-T cell therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Ruihong","family":"Zuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Meijie","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"4087_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104751","volume":"211","author":"A Suchiita","year":"2025","unstructured":"Suchiita A, Sonkar SC. Revolutionizing immunotherapy: the next frontier in CAR T-cell engineering. Crit Rev Oncol Hematol. 2025;211:104751.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4087_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101147","volume":"62","author":"JS Wang","year":"2025","unstructured":"Wang JS, Schellenberg SJ, Demeros A, Lin AY. Exosomes in review: a new frontier in CAR-T cell therapies. Neoplasia. 2025;62:101147.","journal-title":"Neoplasia"},{"issue":"1","key":"4087_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s43046-025-00262-6","volume":"37","author":"SS Jangavali","year":"2025","unstructured":"Jangavali SS, Hangargekar PB, Gangthade BU, Jadhav SA, Havelikar UA, Joshi AA. From lab to lifesaver: the rise of CAR T-cell therapy in oncology. J Egypt Natl Canc Inst. 2025;37(1):37.","journal-title":"J Egypt Natl Canc Inst"},{"key":"4087_CR4","doi-asserted-by":"publisher","first-page":"1178403","DOI":"10.3389\/fimmu.2023.1178403","volume":"14","author":"NJ Fergusson","year":"2023","unstructured":"Fergusson NJ, Adeel K, Kekre N, Atkins H, Hay KA. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells. Front Immunol. 2023;14:1178403.","journal-title":"Front Immunol"},{"issue":"1","key":"4087_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1186\/s12885-024-12651-6","volume":"24","author":"E Montagna","year":"2024","unstructured":"Montagna E, de Campos NSP, Porto VA, da Silva GCP, Suarez ER. CD19 CAR t cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient\u2019s age, and tumor types. BMC Cancer. 2024;24(1):1037.","journal-title":"BMC Cancer"},{"issue":"19","key":"4087_CR6","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"1","key":"4087_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"4087_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. Car-t cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4087_CR9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4049\/jimmunol.2001249","volume":"206","author":"VET Tedesco","year":"2021","unstructured":"Tedesco VET, Mohan C. Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T cell therapy. J immunol. 2021;206(7):1561\u20138.","journal-title":"J immunol"},{"issue":"1","key":"4087_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4.","journal-title":"Biomark Res"},{"issue":"1","key":"4087_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"key":"4087_CR12","doi-asserted-by":"publisher","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","volume":"14","author":"D Shah","year":"2023","unstructured":"Shah D, Soper B, Shopland L. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. Front Immunol. 2023;14:1190379.","journal-title":"Front Immunol"},{"key":"4087_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.103016","volume":"69","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhu L, Li X, Ge C, Pei W, Zhang M, et al. M2 macrophage exosome-derived lncRNA AK083884 protects mice from CVB3-induced viral myocarditis through regulating PKM2\/HIF-1\u03b1 axis mediated metabolic reprogramming of macrophages. Redox Biol. 2024;69:103016.","journal-title":"Redox Biol"},{"issue":"9","key":"4087_CR14","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","volume":"28","author":"P Sharma","year":"2022","unstructured":"Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan WW, et al. FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2022;28(9):1759\u201364.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4087_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"4087_CR16","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"4087_CR17","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4087_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143(5):404\u201316.","journal-title":"Blood"},{"issue":"9","key":"4087_CR19","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394.","journal-title":"Nat Med"},{"key":"4087_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967720.61024.68","author":"N Munshi","year":"2023","unstructured":"Munshi N, Martin T, Usmani SZ, Berdeja J, Jakubowiak A, Agha M, et al. S202: cartitude-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. HemaSphere. 2023. https:\/\/doi.org\/10.1097\/01.HS9.0000967720.61024.68.","journal-title":"HemaSphere"},{"key":"4087_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2023.104367","volume":"142","author":"A Bogatu","year":"2023","unstructured":"Bogatu A, Wysocka M, Wysocki O, Butterworth H, Pillai M, Allison J, et al. Meta-analysis informed machine learning: supporting cytokine storm detection during CAR-T cell therapy. J Biomed Inform. 2023;142:104367.","journal-title":"J Biomed Inform"},{"issue":"1","key":"4087_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","journal-title":"J Exp Clin Cancer Res"},{"key":"4087_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104912","author":"F Zhang","year":"2025","unstructured":"Zhang F, Samarkhazan HS, Pooraskari Z, Bayani A. Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy. Crit Rev Oncol Hematol. 2025. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104912.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4087_CR24","doi-asserted-by":"publisher","first-page":"1371743","DOI":"10.3389\/fimmu.2024.1371743","volume":"15","author":"L Cigalotto","year":"2024","unstructured":"Cigalotto L, Martinvalet D. Granzymes in health and diseases: the good, the bad and the ugly. Front Immunol. 2024;15:1371743.","journal-title":"Front Immunol"},{"issue":"43","key":"4087_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7969","volume":"5","author":"Y Liu","year":"2020","unstructured":"Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al. Gasdermin E\u2013mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43):eaax7969.","journal-title":"Sci Immunol"},{"issue":"1\u20132","key":"4087_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/17534259221143216","volume":"29","author":"X Ouyang","year":"2023","unstructured":"Ouyang X, Zhou J, Lin L, Zhang Z, Luo S, Hu D. Pyroptosis, inflammasome, and gasdermins in tumor immunity. Innate Immun. 2023;29(1\u20132):3\u201313.","journal-title":"Innate Immun"},{"issue":"1","key":"4087_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","volume":"28","author":"M Bellal","year":"2024","unstructured":"Bellal M, Malherbe J, Damaj G, Du Cheyron D. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update. Crit Care. 2024;28(1):69.","journal-title":"Crit Care"},{"issue":"7","key":"4087_CR28","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Hill JA, Dahiya S, Jain MD. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med. 2025;31(7):2132\u201346.","journal-title":"Nat Med"},{"issue":"1","key":"4087_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","volume":"4","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Han W. Management of cytokine release syndrome (CRS) following CAR T-cell therapy: a comprehensive review. Clin Cancer Bull. 2025;4(1):15.","journal-title":"Clin Cancer Bull"},{"issue":"2","key":"4087_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4087_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-021-00764-4","volume":"6","author":"X Li","year":"2021","unstructured":"Li X, Shao M, Zeng X, Qian P, Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther. 2021;6(1):367.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4087_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/MAT.0000000000001886","volume":"69","author":"KT Nguyen","year":"2023","unstructured":"Nguyen KT, Hecking J, Berg IC, Kannappan R, Donoghue L, Ismail E, et al. Von Willebrand factor and Angiopoietin-2 are sensitive biomarkers of pulsatility in continuous-flow ventricular assist device patients. ASAIO J. 2023;69(6):569\u201375.","journal-title":"ASAIO J"},{"issue":"1","key":"4087_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-025-00727-7","volume":"23","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Khaksari MN, Rahmati A, Esfahani ML, Solouki A, Aghaei M. Von willebrand disease (VWD) and pregnancy: a comprehensive overview. Thromb J. 2025;23(1):41.","journal-title":"Thromb J"},{"issue":"4","key":"4087_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/curroncol32040198","volume":"32","author":"P Arvanitis","year":"2025","unstructured":"Arvanitis P, Tziotis A, Papadimatos S, Farmakiotis D. Pathogenesis, diagnosis, and management of cytokine release syndrome in patients with cancer: focus on infectious disease considerations. Curr Oncol. 2025;32(4):198.","journal-title":"Curr Oncol"},{"issue":"2","key":"4087_CR35","doi-asserted-by":"publisher","first-page":"2263229","DOI":"10.1080\/21645515.2023.2263229","volume":"19","author":"H-Q Zhang","year":"2023","unstructured":"Zhang H-Q, Cao B-Z, Cao Q-T, Hun M, Cao L, Zhao M-Y. An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination. Hum Vaccin Immunother. 2023;19(2):2263229.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"4087_CR36","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1038\/ncomms6962","volume":"6","author":"L Hakanpaa","year":"2015","unstructured":"Hakanpaa L, Sipila T, Leppanen V-M, Gautam P, Nurmi H, Jacquemet G, et al. Endothelial destabilization by angiopoietin-2 via integrin \u03b21 activation. Nat Commun. 2015;6(1):5962.","journal-title":"Nat Commun"},{"issue":"21","key":"4087_CR37","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306.","journal-title":"Blood"},{"issue":"4","key":"4087_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10456-020-09730-0","volume":"23","author":"DM Smadja","year":"2020","unstructured":"Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;23(4):611\u201320.","journal-title":"Angiogenesis"},{"key":"4087_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172876","author":"C Demosthenous","year":"2025","unstructured":"Demosthenous C, Evangelidis P, Gatsis A, Mitroulis I, Vakalopoulou S, Vardi A, et al. Endothelial injury following CAR-T cell immunotherapy for hematological malignancies. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17172876.","journal-title":"Cancers (Basel)"},{"key":"4087_CR40","unstructured":"Balli S SK, Sharan S. Physiology, Fever. StatPearls [Internet]. 2023."},{"issue":"4","key":"4087_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/1073858418760481","volume":"24","author":"A Blomqvist","year":"2018","unstructured":"Blomqvist A, Engblom D. Neural mechanisms of inflammation-induced fever. Neuroscientist. 2018;24(4):381\u201399.","journal-title":"Neuroscientist"},{"issue":"48","key":"4087_CR42","doi-asserted-by":"publisher","first-page":"15957","DOI":"10.1523\/JNEUROSCI.3520-14.2014","volume":"34","author":"A Eskilsson","year":"2014","unstructured":"Eskilsson A, Mirrasekhian E, Dufour S, Schwaninger M, Engblom D, Blomqvist A. Immune-induced fever is mediated by IL-6 receptors on brain endothelial cells coupled to STAT3-dependent induction of brain endothelial prostaglandin synthesis. J Neurosci. 2014;34(48):15957\u201361.","journal-title":"J Neurosci"},{"issue":"12","key":"4087_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvh.13886","volume":"30","author":"Q Ning","year":"2023","unstructured":"Ning Q, Yang T, Guo X, Huang Y, Gao Y, Liu M, et al. CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes. J Viral Hepat. 2023;30(12):951\u20138.","journal-title":"J Viral Hepat"},{"issue":"4","key":"4087_CR44","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1021\/acsnano.3c05847","volume":"18","author":"W Pei","year":"2024","unstructured":"Pei W, Zhang Y, Zhu X, Zhao C, Li X, L\u00fc H, et al. Multitargeted immunomodulatory therapy for viral myocarditis by engineered extracellular vesicles. ACS Nano. 2024;18(4):2782\u201399.","journal-title":"ACS Nano"},{"issue":"7","key":"4087_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtct.2025.03.011","volume":"31","author":"R Shouval","year":"2025","unstructured":"Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, et al. Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma. Transplant Cell Ther. 2025;31(7):419\u201333.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"4087_CR46","doi-asserted-by":"publisher","first-page":"2169958","DOI":"10.1080\/26895293.2023.2169958","volume":"16","author":"V Alende-Castro","year":"2023","unstructured":"Alende-Castro V, Alonso-Sampedro M, Fern\u00e1ndez-Merino C, Sope\u00f1a B, Vidal C, Gude F, et al. Factors influencing serum concentrations of soluble interleukin-2 receptor: a general adult population study. All Life. 2023;16(1):2169958.","journal-title":"All Life"},{"key":"4087_CR47","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T Cell\u2013associated neurotoxicity. Front Immunol. 2020;11:577027.","journal-title":"Front Immunol"},{"issue":"4","key":"4087_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1012908","volume":"21","author":"DS Santurio","year":"2025","unstructured":"Santurio DS, Barros LRC, Glauche I, Fassoni AC. Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome. PLoS Comput Biol. 2025;21(4):e1012908.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"4087_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.","journal-title":"J Hematol Oncol"},{"key":"4087_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202200130","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu L, Ma C, Chen W. A computational model of cytokine release syndrome during CAR T-cell therapy. Adv Ther. 2022. https:\/\/doi.org\/10.1002\/adtp.202200130.","journal-title":"Adv Ther"},{"issue":"2","key":"4087_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2023.100367","volume":"11","author":"C Nwozichi","year":"2024","unstructured":"Nwozichi C, Ogunmuyiwa AO, Ojewale MO. Nurses\u2019 roles in CAR-T therapy for B-cell malignancies and managing associated cytokine release syndrome. Asia-Pac J Oncol Nurs. 2024;11(2):100367.","journal-title":"Asia-Pac J Oncol Nurs"},{"issue":"6","key":"4087_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2023.151505","volume":"39","author":"M Steinbach","year":"2023","unstructured":"Steinbach M, Zitella LJ, Florendo E, Lee E, Riccobono C, DiFilippo H, et al. Nursing care throughout the chimeric antigen receptor T-cell therapy process for multiple myeloma. Semin Oncol Nurs. 2023;39(6):151505.","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"4087_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2024.151621","volume":"40","author":"D Catamero","year":"2024","unstructured":"Catamero D, Benito PB, Shenoy S, Doyle M, Fowler J, Kobos R, et al. Nursing considerations for cytokine release syndrome in relapsed\/refractory multiple myeloma: experience with teclistamab from the MajesTEC-1 Study. Semin Oncol Nurs. 2024;40(3):151621.","journal-title":"Semin Oncol Nurs"},{"key":"4087_CR54","doi-asserted-by":"publisher","first-page":"1396490","DOI":"10.3389\/fonc.2024.1396490","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol. 2024;14:1396490.","journal-title":"Front Oncol"},{"issue":"1","key":"4087_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","volume":"48","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez C, McEvoy C, Munshi L, Stephens RS, Detsky ME, Nates JL, et al. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit Care Med. 2020;48(1):10\u201321.","journal-title":"Crit Care Med"},{"issue":"20","key":"4087_CR56","first-page":"2452","volume":"141","author":"C Gutierrez","year":"2023","unstructured":"Gutierrez C, Neilan TG, Grover NS. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood. 2023;141(20):2452\u20139.","journal-title":"Blood"},{"issue":"9","key":"4087_CR57","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1164\/rccm.202005-2046OC","volume":"202","author":"R Panwar","year":"2020","unstructured":"Panwar R, Madotto F, Laffey JG, van Haren FMP. Compliance phenotypes in early acute respiratory distress syndrome before the COVID-19 pandemic. Am J Respir Crit Care Med. 2020;202(9):1244\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"4087_CR58","doi-asserted-by":"publisher","first-page":"1383255","DOI":"10.3389\/fimmu.2024.1383255","volume":"15","author":"L Huang","year":"2024","unstructured":"Huang L, Tan J, Lin P, Chen Z, Huang Q, Yao H, et al. Autoimmune encephalitis followed by hemophagocytic lymph histiocytosis: a case report. Front Immunol. 2024;15:1383255.","journal-title":"Front Immunol"},{"issue":"6","key":"4087_CR59","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","volume":"20","author":"CK Chou","year":"2020","unstructured":"Chou CK, Turtle CJ. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 2020;20(6):653\u201364.","journal-title":"Expert Opin Biol Ther"},{"key":"4087_CR60","doi-asserted-by":"publisher","first-page":"1553966","DOI":"10.3389\/fmed.2025.1553966","volume":"12","author":"E Gavriilaki","year":"2025","unstructured":"Gavriilaki E, Tzannou I, Vardi A, Tsonis I, Liga M, Gkirkas K, et al. Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece. Front Med. 2025;12:1553966.","journal-title":"Front Med"},{"issue":"2","key":"4087_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2023.100367","volume":"11","author":"C Nwozichi","year":"2024","unstructured":"Nwozichi C, Ogunmuyiwa AO, Ojewale MO. Nurses\u2019 roles in CAR-T therapy for B-cell malignancies and managing associated cytokine release syndrome. Asia Pac J Oncol Nurs. 2024;11(2):100367.","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"8","key":"4087_CR62","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist"},{"key":"4087_CR63","doi-asserted-by":"publisher","first-page":"1530623","DOI":"10.3389\/fimmu.2025.1530623","volume":"16","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, An Y, Zhang X, Xiao X, Bai X, Liu P, et al. Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Front Immunol. 2025;16:1530623.","journal-title":"Front Immunol"},{"issue":"3\u20134","key":"4087_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes AD, Teachey DT, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol. 2024;46(3\u20134):5.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"4087_CR65","first-page":"367","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Experim Clin Cancer Res CR. 2021;40(1):367.","journal-title":"J Experim Clin Cancer Res CR"},{"key":"4087_CR66","doi-asserted-by":"publisher","first-page":"1450173","DOI":"10.3389\/fimmu.2024.1450173","volume":"15","author":"M Su","year":"2024","unstructured":"Su M, Chen L, Xie L, Fleurie A, Jonquieres R, Cao Q, et al. Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy. Front Immunol. 2024;15:1450173.","journal-title":"Front Immunol"},{"issue":"5","key":"4087_CR67","first-page":"220","volume":"78","author":"WA Dik","year":"2020","unstructured":"Dik WA, Heron M. Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases. Neth J Med. 2020;78(5):220\u201331.","journal-title":"Neth J Med"},{"issue":"26","key":"4087_CR68","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/bloodadvances.2017012310","volume":"1","author":"A Hayden","year":"2017","unstructured":"Hayden A, Lin M, Park S, Pudek M, Schneider M, Jordan MB, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv. 2017;1(26):2529\u201334.","journal-title":"Blood Adv"},{"key":"4087_CR69","doi-asserted-by":"publisher","first-page":"1110647","DOI":"10.3389\/fneur.2023.1110647","volume":"14","author":"OH Butt","year":"2023","unstructured":"Butt OH, Zhou AY, Ances BM, DiPersio JF, Ghobadi A. A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Front Neurol. 2023;14:1110647.","journal-title":"Front Neurol"},{"issue":"6","key":"4087_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. WIREs Mech Dis. 2022;14(6):e1576.","journal-title":"WIREs Mech Dis"},{"issue":"35","key":"4087_CR71","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncol"},{"key":"4087_CR72","doi-asserted-by":"publisher","DOI":"10.2174\/1874321801711010035","author":"S Batool","year":"2017","unstructured":"Batool S, Garg R. Appropriate use of oxygen delivery devices. Open Anesthesiol J. 2017. https:\/\/doi.org\/10.2174\/1874321801711010035.","journal-title":"Open Anesthesiol J"},{"issue":"1","key":"4087_CR73","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12912-023-01592-3","volume":"22","author":"H Baek","year":"2023","unstructured":"Baek H, Han K, Cho H, Ju J. Nursing teamwork is essential in promoting patient-centered care: a cross-sectional study. BMC Nurs. 2023;22(1):433.","journal-title":"BMC Nurs"},{"key":"4087_CR74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2020.00085","volume":"10","author":"M Taberna","year":"2020","unstructured":"Taberna M, Gil Moncayo F, Jan\u00e9-Salas E, Antonio M, Arribas L, Vilajosana E, et al. The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020;10:85.","journal-title":"Front Oncol"},{"key":"4087_CR75","doi-asserted-by":"crossref","unstructured":"Hakami A, Hussain F, Bakheet A, Alghamdi K, AlAtrash K. Nursing research priorities based on the nurse-sensitive indicators: scoping review. Open Nurs J. 2023;17","DOI":"10.2174\/18744346-v17-e230508-2023-29"},{"key":"4087_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnsa.2024.100227","volume":"7","author":"E Gormley","year":"2024","unstructured":"Gormley E, Connolly M, Ryder M. The development of nursing-sensitive indicators: a critical discussion. Int J Nurs Stud Adv. 2024;7:100227.","journal-title":"Int J Nurs Stud Adv"},{"issue":"2","key":"4087_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.outlook.2025.102379","volume":"73","author":"NL McEvoy","year":"2025","unstructured":"McEvoy NL, Kalvas LB, Walsh K, Curley MAQ. The identification and characterization of nurse-sensitive outcomes in acute and critical care: a systematic review. Nurs Outlook. 2025;73(2):102379.","journal-title":"Nurs Outlook"},{"issue":"1","key":"4087_CR78","first-page":"21","volume":"5","author":"AH Miles","year":"2016","unstructured":"Miles AH, Spaeder MC, Stockwell DC. Unplanned ICU transfers from inpatient units: examining the prevalence and preventability of adverse events associated with ICU transfer in pediatrics. J Pediatr Intensive Care. 2016;5(1):21\u20137.","journal-title":"J Pediatr Intensive Care"},{"issue":"1","key":"4087_CR79","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13049-025-01371-w","volume":"33","author":"MA Torvik","year":"2025","unstructured":"Torvik MA, Nymo SH, Nymo SH, Ofstad EH. Unplanned transfers from wards to intensive care units: how well does NEWS identify patients in need of urgent escalation of care? Scand J Trauma Resusc Emerg Med. 2025;33(1):105.","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"4087_CR80","doi-asserted-by":"publisher","DOI":"10.17533\/udea.iee.v41n3e03","author":"EA Feller","year":"2023","unstructured":"Feller EA, Di Mario S, Filomeno L, La Torre G. Nursing sensitive outcomes evaluation in the emergency department: an umbrella review. Investig Educ Enferm. 2023. https:\/\/doi.org\/10.17533\/udea.iee.v41n3e03.","journal-title":"Investig Educ Enferm"},{"issue":"7237","key":"4087_CR81","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/bmj.320.7237.741","volume":"320","author":"EJ Thomas","year":"2000","unstructured":"Thomas EJ, Brennan TA. Incidence and types of preventable adverse events in elderly patients: population based review of medical records. BMJ (Clinical research ed). 2000;320(7237):741\u20134.","journal-title":"BMJ (Clinical research ed)"},{"key":"4087_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssci.2023.106200","volume":"165","author":"GAL Kennedy","year":"2023","unstructured":"Kennedy GAL, Pedram S, Sanzone S. Improving safety outcomes through medical error reduction via virtual reality-based clinical skills training. Saf Sci. 2023;165:106200.","journal-title":"Saf Sci"},{"key":"4087_CR83","unstructured":"Rodziewicz TL, Houseman B, Vaqar S, Hipskind JE. Medical Error Reduction and Prevention. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Benjamin Houseman declares no relevant financial relationships with ineligible companies. Disclosure: Sarosh Vaqar declares no relevant financial relationships with ineligible companies. Disclosure: John Hipskind declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"5","key":"4087_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251546","volume":"16","author":"JD Veldhuizen","year":"2021","unstructured":"Veldhuizen JD, van den Bulck AOE, Elissen AMJ, Mikkers MC, Schuurmans MJ, Bleijenberg N. Nurse-sensitive outcomes in district nursing care: a Delphi study. PLoS ONE. 2021;16(5):e0251546.","journal-title":"PLoS ONE"},{"issue":"10","key":"4087_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2024.100579","volume":"11","author":"A Gupta","year":"2024","unstructured":"Gupta A, Dagar G, Rehmani MU, Prasad CP, Saini D, Singh M, et al. Car T-cell therapy in cancer: integrating nursing perspectives for enhanced patient care. Asia-Pac J Oncol Nurs. 2024;11(10):100579.","journal-title":"Asia-Pac J Oncol Nurs"},{"issue":"1","key":"4087_CR86","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5737\/236880762717480","volume":"27","author":"G Jeyathevan","year":"2017","unstructured":"Jeyathevan G, Lemonde M, Brathwaite AC. The role of oncology nurse navigators in facilitating continuity of care within the diagnostic phase for adult patients with lung cancer. Canadian Oncol Nurs J Revue Canadienne de Nursing Oncologique. 2017;27(1):74\u201380.","journal-title":"Canadian Oncol Nurs J Revue Canadienne de Nursing Oncologique"},{"issue":"20","key":"4087_CR87","volume":"12","author":"Y Gong","year":"2025","unstructured":"Gong Y, Fei P, Zhang Y, Xu Y, Wei J. From multi-omics to visualization and beyond: bridging micro and macro insights in CAR-T cell therapy. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2025;12(20):e2501095.","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"4","key":"4087_CR88","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","volume":"20","author":"J Yang","year":"2023","unstructured":"Yang J, Chen Y, Jing Y, Green MR, Han L. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Rev Clin Oncol. 2023;20(4):211\u201328.","journal-title":"Nat Rev Clin Oncol"},{"key":"4087_CR89","doi-asserted-by":"publisher","unstructured":"Xu H, Xu L-Z, Huai R-P, Zhang C, Suo S-N, Li Y-Q, et al. A lysosome-targetable fluorescent probe for the ratiometric detection of formaldehyde in living cells and in vivo\u2020\u2020Electronic supplementary information (ESI) available: Spectral data, copies of 1H\/13C NMR and ESI-MS spectra and other materials. See https:\/\/doi.org\/10.1039\/d3ob00888f. Organ Biomol Chem 2023;21(31):6405\u20139.","DOI":"10.1039\/d3ob00888f"},{"key":"4087_CR90","doi-asserted-by":"crossref","unstructured":"Role of the oncology nurse navigator throughout the cancer trajectory. Oncol Nurs Forum. 2018;45(3):283.","DOI":"10.1188\/18.ONF.283"},{"key":"4087_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.929736","volume":"13","author":"H Abdelhalim","year":"2022","unstructured":"Abdelhalim H, Berber A, Lodi M, Jain R, Nair A, Pappu A, et al. Artificial intelligence, healthcare, clinical genomics, and pharmacogenomics approaches in precision medicine. Front Genet. 2022;13:929736.","journal-title":"Front Genet"},{"issue":"5","key":"4087_CR92","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ipha.2024.08.005","volume":"2","author":"H Taherdoost","year":"2024","unstructured":"Taherdoost H, Ghofrani A. AI\u2019s role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. Intellig Pharm. 2024;2(5):643\u201350.","journal-title":"Intellig Pharm"},{"key":"4087_CR93","doi-asserted-by":"crossref","unstructured":"Blasiak A, Truong ATL, Foo N, Tan LWJ, Kumar KS, Tan S-B, et al. Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial. NPJ Precis Oncol 2025;9(1):49.","DOI":"10.1038\/s41698-025-00835-7"},{"issue":"1","key":"4087_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01858-x","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H. Integrating multi-omics approaches in acute myeloid leukemia (AML): advancements and clinical implications. Clin Exp Med. 2025;25(1):311.","journal-title":"Clin Exp Med"},{"key":"4087_CR95","unstructured":"Using nurse navigators to improve timeliness of biomarker testing for non-small cell lung cancer. Clin J Oncol Nurs 2024;28(6):589\u201392."},{"key":"4087_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2023.107720","volume":"112","author":"EE Fortune","year":"2023","unstructured":"Fortune EE, Zaleta AK, Saxton MC. Biomarker testing communication, familiarity, and informational needs among people living with breast, colorectal, and lung cancer. Patient Educ Couns. 2023;112:107720.","journal-title":"Patient Educ Couns"},{"issue":"W1","key":"4087_CR97","doi-asserted-by":"publisher","first-page":"W520","DOI":"10.1093\/nar\/gkad408","volume":"51","author":"F-C Qian","year":"2023","unstructured":"Qian F-C, Zhou L-W, Li Y-Y, Yu Z-M, Li L-D, Wang Y-Z, et al. SEanalysis 2.0: a comprehensive super-enhancer regulatory network analysis tool for human and mouse. Nucleic Acids Res. 2023;51(W1):W520\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4087_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55094-0","volume":"15","author":"W He","year":"2024","unstructured":"He W, Zhu J, Feng Y, Liang F, You K, Chai H, et al. Neuromorphic-enabled video-activated cell sorting. Nat Commun. 2024;15(1):10792.","journal-title":"Nat Commun"},{"key":"4087_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.134042","volume":"1271","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou Y, Lei J, Lu Q, Qin X, Xu Q, et al. A NIR fluorescent probe for the selective detection of hydrogen peroxide by acetyl-hydrolyzing in cells. J Mol Struct. 2023;1271:134042.","journal-title":"J Mol Struct"},{"issue":"4","key":"4087_CR100","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.cclet.2021.11.051","volume":"33","author":"S Liu","year":"2022","unstructured":"Liu S, He X, Zhang T, Zhao K, Xiao C, Tong Z, et al. Highly sensitive smartphone-based detection of Listeria monocytogenes using SYTO9. Chin Chem Lett. 2022;33(4):1933\u20135.","journal-title":"Chin Chem Lett"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04087-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04087-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04087-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:11:44Z","timestamp":1774415504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04087-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":100,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4087"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04087-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}